XML 69 R58.htm IDEA: XBRL DOCUMENT
v3.7.0.1

Collaboration and Licensing Revenue - Summarized Collaboration and Licensing Revenues (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 30, 2017 | Jun. 30, 2016 | Jun. 30, 2017 | Jun. 30, 2016
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Collaboration and licensing revenues | $ 28,164 |  | $ 27,481 |  | $ 61,229 |  | $ 51,554 |
Upfront and Milestone Payments |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Collaboration and licensing revenues | 10,424 |  | 8,055 |  | 21,748 |  | 13,827 |
Research and Development Services |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Collaboration and licensing revenues | 17,740 |  | 19,426 |  | 39,481 |  | 37,727 |
ZIOPHARM Oncology, Inc. |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Collaboration and licensing revenues | 9,964 |  | 6,970 |  | 20,949 |  | 13,951 |
ZIOPHARM Oncology, Inc. | Upfront and Milestone Payments |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Collaboration and licensing revenues | 4,842 |  | 922 |  | 9,684 |  | 1,844 |
ZIOPHARM Oncology, Inc. | Research and Development Services |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Collaboration and licensing revenues | 5,122 |  | 6,048 |  | 11,265 |  | 12,107 |
Oragenics, Inc. |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Collaboration and licensing revenues | 475 |  | 507 |  | 1,044 |  | 1,313 |
Oragenics, Inc. | Upfront and Milestone Payments |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Collaboration and licensing revenues | 261 |  | 261 |  | 524 |  | 524 |
Oragenics, Inc. | Research and Development Services |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Collaboration and licensing revenues | 214 |  | 246 |  | 520 |  | 789 |
Fibrocell Science, Inc. |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Collaboration and licensing revenues | 1,953 |  | 1,394 |  | 3,692 |  | 3,251 |
Fibrocell Science, Inc. | Upfront and Milestone Payments |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Collaboration and licensing revenues | 605 |  | 605 |  | 1,210 |  | 1,210 |
Fibrocell Science, Inc. | Research and Development Services |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Collaboration and licensing revenues | 1,348 |  | 789 |  | 2,482 |  | 2,041 |
Genopaver, LLC |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Collaboration and licensing revenues | 1,513 |  | 1,637 |  | 3,193 |  | 3,215 |
Genopaver, LLC | Upfront and Milestone Payments |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Collaboration and licensing revenues | 68 |  | 68 |  | 137 |  | 137 |
Genopaver, LLC | Research and Development Services |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Collaboration and licensing revenues | 1,445 |  | 1,569 |  | 3,056 |  | 3,078 |
S & I Ophthalmic, LLC |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Collaboration and licensing revenues | 72 |  | 2,358 |  | 375 |  | 3,544 |
S & I Ophthalmic, LLC | Upfront and Milestone Payments |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Collaboration and licensing revenues | 0 |  | 0 |  | 0 |  | 0 |
S & I Ophthalmic, LLC | Research and Development Services |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Collaboration and licensing revenues | 72 |  | 2,358 |  | 375 |  | 3,544 |
OvaXon, LLC |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Collaboration and licensing revenues | 880 |  | 808 |  | 1,704 |  | 1,502 |
OvaXon, LLC | Upfront and Milestone Payments |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Collaboration and licensing revenues | 0 |  | 0 |  | 0 |  | 0 |
OvaXon, LLC | Research and Development Services |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Collaboration and licensing revenues | 880 |  | 808 |  | 1,704 |  | 1,502 |
Intrexon Energy Partners, LLC |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Collaboration and licensing revenues | 1,920 |  | 4,212 |  | 7,006 |  | 8,200 |
Intrexon Energy Partners, LLC | Upfront and Milestone Payments |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Collaboration and licensing revenues | 625 |  | 625 |  | 1,250 |  | 1,250 |
Intrexon Energy Partners, LLC | Research and Development Services |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Collaboration and licensing revenues | 1,295 |  | 3,587 |  | 5,756 |  | 6,950 |
Persea Bio, LLC |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Collaboration and licensing revenues | 266 |  | 331 |  | 555 |  | 655 |
Persea Bio, LLC | Upfront and Milestone Payments |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Collaboration and licensing revenues | 125 |  | 125 |  | 250 |  | 250 |
Persea Bio, LLC | Research and Development Services |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Collaboration and licensing revenues | 141 |  | 206 |  | 305 |  | 405 |
Ares Trading S.A. |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Collaboration and licensing revenues | 2,803 |  | 2,218 |  | 6,118 |  | 4,623 |
Ares Trading S.A. | Upfront and Milestone Payments |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Collaboration and licensing revenues | 1,597 |  | 1,597 |  | 3,194 |  | 3,194 |
Ares Trading S.A. | Research and Development Services |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Collaboration and licensing revenues | 1,206 |  | 621 |  | 2,924 |  | 1,429 |
Intrexon Energy Partners II, LLC |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Collaboration and licensing revenues | 956 |  | 894 |  | 2,105 |  | 1,444 |
Intrexon Energy Partners II, LLC | Upfront and Milestone Payments |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Collaboration and licensing revenues | 500 |  | 500 |  | 1,000 |  | 1,000 |
Intrexon Energy Partners II, LLC | Research and Development Services |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Collaboration and licensing revenues | 456 |  | 394 |  | 1,105 |  | 444 |
Intrexon T1D Partners, LLC |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Collaboration and licensing revenues | 1,288 |  | 310 |  | 2,420 |  | 310 |
Intrexon T1D Partners, LLC | Upfront and Milestone Payments |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Collaboration and licensing revenues | 272 |  | 278 |  | 536 |  | 278 |
Intrexon T1D Partners, LLC | Research and Development Services |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Collaboration and licensing revenues | 1,016 |  | 32 |  | 1,884 |  | 32 |
Harvest start-up entities |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Collaboration and licensing revenues | 4,452 | [1] | 939 | [2] | 7,815 | [3] | 1,373 | [4]
Harvest start-up entities | Upfront and Milestone Payments |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Collaboration and licensing revenues | 606 | [1] | 305 | [2] | 1,207 | [3] | 351 | [4]
Harvest start-up entities | Research and Development Services |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Collaboration and licensing revenues | 3,846 | [1] | 634 | [2] | 6,608 | [3] | 1,022 | [4]
Other |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Collaboration and licensing revenues | 1,622 |  | 4,903 |  | 4,253 |  | 8,173 |
Other | Upfront and Milestone Payments |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Collaboration and licensing revenues | 923 |  | 2,769 |  | 2,756 |  | 3,789 |
Other | Research and Development Services |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Collaboration and licensing revenues | $ 699 |  | $ 2,134 |  | $ 1,497 |  | $ 4,384 |
[1] | For the three months ended June 30, 2017, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc.
[2] | For the three months ended June 30, 2016, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and Relieve Genetics, Inc.
[3] | For the six months ended June 30, 2017, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc.
[4] | For the six months ended June 30, 2016, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and Relieve Genetics, Inc.

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue from contractual agreements with collaborators whereby the collaborators obtain exclusive access to the entity's proprietary technologies for use in the research, development and commercialization of products and/or treatments in a contractually specified field of use as well as revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Includes revenue recognized from upfront payments received upon consummation of the agreement, reimbursements for costs incurred by the entity for research and development efforts, and milestone payments received upon achievement of specified development, regulatory and commercial activities as defined in the collaboration and licensing agreements. + References No definition available. + Details
Name: | xon_CollaborationAndLicensingRevenue
Namespace Prefix: | xon_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_ProductOrServiceAxis=xon_UpfrontAndMilestonePaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=xon_ResearchAndDevelopmentServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_ZiopharmMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_OragenicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_FibrocellMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_GenopaverLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_SIOphthalmicMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_OvaXonMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_IntrexonEnergyPartnersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_PerseaBioLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_AresTradingS.A.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_IntrexonEnergyPartnersIILLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_IntrexonT1DPartnersLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_HarvestStartUpEntitiesAggregatedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_OtherCollaborationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |